Language:

The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study

Clinical therapeutics, 2008-04, Vol.30 (4), p.587-604 [Peer Reviewed Journal]

Excerpta Medica Inc. ;2008 Excerpta Medica Inc. ;2008 INIST-CNRS ;ISSN: 0149-2918 ;EISSN: 1879-114X ;DOI: 10.1016/j.clinthera.2008.04.002 ;PMID: 18498909

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study
Author: Chrysant, Steven G., MD, PhD ; Melino, Michael, PhD ; Karki, Sulekha, BAMS ; Lee, James, PhD ; Heyrman, Reinilde, MD
Subjects: Aged ; Amlodipine - administration & dosage ; amlodipine besylate ; Angiotensin II Type 1 Receptor Blockers - administration & dosage ; Antihypertensives ; Arterial hypertension. Arterial hypotension ; Biological and medical sciences ; Blood and lymphatic vessels ; Blood pressure ; Blood Pressure - drug effects ; Blood Pressure - physiology ; Blood Pressure Monitoring, Ambulatory ; Calcium Channel Blockers - administration & dosage ; Cardiology. Vascular system ; Cardiovascular disease ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Therapy, Combination ; Edema ; Enzymes ; Female ; fixed-dose combination ; Follow-Up Studies ; Heart attacks ; Humans ; Hypertension ; Hypertension - drug therapy ; Hypertension - physiopathology ; Imidazoles - administration & dosage ; Internal Medicine ; Male ; Medical Education ; Medical sciences ; Middle Aged ; Mortality ; Olmesartan Medoxomil ; Pharmacology. Drug treatments ; Prevention ; Severity of Illness Index ; Tetrazoles - administration & dosage ; Treatment Outcome
Is Part Of: Clinical therapeutics, 2008-04, Vol.30 (4), p.587-604
Description: Abstract Background: Hypertension guidelines recommend the use of 2 agents having complementary mechanisms of action when >1 agent is needed to achieve blood pressure (BP) goals. Objective: The aim of this study was to compare the efficacy and tolerability of combinations of olmesartan medoxomil (OM) and amlodipine besylate with those of the component monotherapies in patients with mild to severe hypertension. Methods: This was a multicenter, randomized, doubleblind, placebo-controlled, factorial study. Patients who were naive to antihypertensive therapy or who underwent a washout of previous antihypertensive therapy for up to 2 weeks and had a seated diastolic BP (SeDBP) of 95 to 120 mm Hg were randomized to receive 1 of the following for 8 weeks: OM 10, 20, or 40 mg; amlodipine (AML) 5 or 10 mg; each possible combination of OM and AML; or placebo. The primary end point was the change from baseline in SeDBP at week 8, with secondary end points including the change in seated systolic blood pressure (SeSBP), the proportion of patients reaching the BP goal (<140/90 mm Hg; <130/80 mm Hg for patients with diabetes), and the proportions of the intention-to-treat population reaching BP thresholds of <120/80, <130/80, <130/85, and <140/90 mm Hg. Safety and tolerability were also evaluated, with a particular focus on the incidence and severity of edema. Results: Of the 1940 randomized patients, 54.3% were male. The mean age of the study population was 54.0 years and 19.8% were aged ≥65 years. The mean baseline BP was 164/102 mm Hg, and 79.3% of patients had stage 2 hypertension. Combination therapy with OM and AML was associated with dose-dependent reductions in SeDBP (from −13.8 mm Hg with OM/AML 10/5 mg to −19.0 mm Hg with OM/AML 40/10 mg) and SeSBP (from −23.6 mm Hg with OM/AML 20/5 mg to −30.1 mm Hg with OM/AML 40/10 mg) that were significantly greater than the reductions with the corresponding component monotherapies ( P < 0.001). At week 8, the number of patients achieving the BP goal ranged from 57 of 163 (35.0%) to 84 of 158 (53.2%) in the combination-therapy groups, from 32 of 160 (20.0%) to 58 of 160 (36.3%) in the OM monotherapy groups, and from 34 of 161 (21.1%) to 53 of 163 (32.5%) in the AML monotherapy groups ( P < 0.005, combination therapies vs component monotherapies), compared with 14 of 160 (8.8%) in the placebo group. Achievement of the BP thresholds was highest in the combination-therapy groups, with 56.3% and 54.0% of patients achieving a BP <140/90 mm Hg with OM/AML 20/10 and 40/10 mg, respectively. Combination therapy was generally well tolerated, and no unexpected safety concerns emerged in the course of the study. The most common adverse events were edema (ranging from 9.9% [OM 20 mg] to 36.8% [AML 10 mg], compared with 12.3% with placebo) and headache (ranging from 2.5% [OM/AML 10/5 mg] to 8.7% [OM 20 mg], compared with 14.2% with placebo). Conclusion: The combination of OM and AML was effective and well tolerated in this adult population with hypertension.
Publisher: Belle Mead, NJ: EM Inc USA
Language: English
Identifier: ISSN: 0149-2918
EISSN: 1879-114X
DOI: 10.1016/j.clinthera.2008.04.002
PMID: 18498909
Source: AUTh Library subscriptions: ProQuest Central
MEDLINE

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study

Excerpta Medica Inc. ;2008 Excerpta Medica Inc. ;2008 INIST-CNRS ;ISSN: 0149-2918 ;EISSN: 1879-114X ;DOI: 10.1016/j.clinthera.2008.04.002 ;PMID: 18498909

Searching Remote Databases, Please Wait